The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Phase 2RecruitingNCT06254690

The First Affiliated Hospital with Nanjing Medical University102 enrolled

Overview

Evaluate the safety and efficacy of Pyrotinib in the transition from low-dose to normal-dose regimen for HER2-positive advanced first-line breast cancer

This study is planned to include 102 patients with HER2-positive advanced breast cancer meeting the admission criteria between 2023-12-01 and 2024-11-01. Statistical software will be used by the randomization officers for 1:1 allocation to pyrotinib dose increasing trial group and normal pyrotinib dose control group . The primary endpoint of this study was grade ≥3 treatment-emergent diarrhea incidence during the first 2 cycles according to Common Terminology Criteria for Adverse Events, version 5.0, and secondary endpoints were adverse effects of pyrotinib during the study, efficacy (progression-free survival and overall survival), and patient-reported outcome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

102

Conditions

Breast Cancer

Interventions

Pyrotinib dose escalationDRUG

Pyrotinib: 240mg in the first week, 320mg in the second week, and 400mg in the third week and thereafter, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)

Pyrotinib dose normalDRUG

Pyrotinib: 400mg per week, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. The subjects voluntarily joins the study and signs the informed consent; 2. Subject is an adult female ≥ 18 years old and ≤ 70 years old at the time of informed consent. 3. HER2-positive advanced breast cancer confirmed by pathology (HER2-positive expression refers to those with at least one tumor cell immunohistochemical staining intensity of 3+ or 2+ positive by fluorescence in situ hybridization \[FISH\] in the pathological examination/review of the primary or metastatic lesion conducted by the pathology department of the Central Hospital) 4. Stage IV breast cancer according to American Joint Committee on Cancer(AJCC) staging system version 8. 5. Subjects did not receive systemic antitumor therapy at the stage of recurrence/metastasis; 6. At least one measurable lesion according to Response Evaluation Criteria In Solid Tumors version 1.1 criteria 7. When randomized, Eastern Cooperative Oncology Group(ECGO) physical fitness status is 0 or 1 point. 8. Vital organ function meets the following requirements (excluding the use of any blood components and cell growth factors during screening) : Absolute neutrophil (ANC) count ≥1.5×109/L; Platelet (PLT) ≥100×109/L; Hemoglobin (HB) ≥9g/dL; Serum albumin ≥3g/dL; Thyroid stimulating hormone (TSH) ≤ULN (if abnormal, T3 and T4 levels should be investigated at the same time, if T3 and T4 levels are normal, they can be included in the group); Bilirubin ≤1.5 ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times ULN; Alkaline phosphatase (AKP) ≤ 2.5 times ULN; Serum creatinine (Cr) ≤1.5 times ULN or creatinine clearance ≥60mL/min. Exclusion Criteria: 1. Any previous tyrosine kinase inhibitor therapy against HER2 target; 2. Patients with known active central nervous system metastases without surgery or radiation therapy, except those who have been stable for at least 1 month after treatment and have been off corticosteroids for \>2 weeks; 3. Pial metastasis confirmed by MRI or lumbar puncture; 4. Inflammatory breast cancer or other malignancies within the previous 5 years, excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; 5. Any antitumor therapy within 4 weeks prior to enrollment; 6. Pregnant or breastfeeding women (women of childbearing age must have a negative pregnancy test within 14 days prior to the first dose, if positive, the pregnancy must be ruled out by ultrasound); 7. Patients with gastrointestinal insufficiency or gastrointestinal disease significantly affecting the absorption of the investigational drug (e.g., uncontrolled ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or resection of the small intestine); 8. Patients with ascites, pleural effusion and pericardial effusion accompanied by clinical symptoms requiring drainage at baseline, or patients with serosal effusion drainage within 4 weeks before the first medication; 9. Patients with a history of immunodeficiency, including HIV testing positive, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 10. Patients with a major surgical procedure or significant trauma within 4 weeks before starting treatment, or expected to undergo major surgery; 11. Concomitant medical conditions (e.g., severe hypertension, diabetes, thyroid disease, co-active hepatitis B/C, and other active infections, etc.) that are deemed by the investigator to seriously endanger the patient's safety or to interfere with the patient's completion of the study; 12. Inability to understand or follow research instructions and requirements; 13. The investigator considers the patient unsuitable for entry into this study.

Locations (1)

Jiangsu Provincial People's Hospital

Nanjing, Jiangsu, China

RECRUITING

Outcomes

Primary Outcomes

Incidence of 2 cycles ≥ grade 3 diarrhea

Grade ≥3 treatment-emergent diarrhea incidence at the end of the first 2 cycles（each cycle is 28 days） according to Common Terminology Criteria for Adverse Events(CTCAE) v5.0.

Time frame: From the date of enrollment to 2 cycles（each cycle is 28 days） of the treatment

Secondary Outcomes

Incidence of Treatment-Emergent Adverse Events

Adverse events include abnormal liver function, myelosuppression and so on.

Time frame: through study completion, an average of 1 year(From the date of enrollment to 30 days after the last dose)

Progression Free Survival

Progression-free survival is defined as the time from the date of randomization to the date of the first documented progression as per local review and according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or death due to any cause.

Time frame: From date of randomization until the date of first documented progression from any cause, whichever came first, assessed up to 100 months

Overall survival

Overall survival is defined as the time from the date of randomization to the date of death due to any cause.

Time frame: From date of randomization until the date of death from any cause, assessed up to 100 months

Patient report outcome

The rating is evaluated by Functional Assessment of Cancer Therapy-Breast scale. It contains questions in five dimensions, with scores ranging from 0 to 4 for each question, with higher scores generally indicating a better quality of life

Time frame: through study completion, an average of 1 year(From the date of enrollment to the clinical outcome from patients' report)

Central Contacts

Yongmei Yin, Ph.D

CONTACT

025-68307102 ymyin@njmu.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.